Notes: March 26, 2020 -- Aptevo Therapeutics Inc. (the “Company”) effected a 1-for-14 reverse stock split of the Company’s outstanding common stock. In particular, each of the Company’s outstanding warrants (CUSIP# 03835L116), in accordance with their terms, will now be exercisable with an exercise price of $18.20 (equal to original exercise price of $1.30 per share times 14) and 0.07142857 shares of common stock for each one share of common stock originally issuable under such warrant (equal to one divided by 14). The outstanding warrants are now exercisable for a total of 1,417,857 shares of common stock. <p> July 11, 2016 -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that, on July 10, 2016, its Board of Directors approved the spin-off of Aptevo Therapeutics Inc. and declared a dividend distribution of one share of Aptevo common stock for every two shares of Emergent common stock outstanding as of the close of business on July 22, 2016, the record date for the distribution. Emergent expects to complete the distribution of Aptevo common stock to Emergent stockholders on August 1, 2016. Aptevo expects its common stock to begin trading on a when issued basis shortly before the July 22, 2016 record date under the ticker APVO WI. When issued trading of Aptevo common stock will continue until the distribution occurs and will settle after the completion of the distribution. Aptevo has applied for listing on the NASDAQ Global Market. On August 1, 2016, Aptevo common stock is expected to begin regular way trading on NASDAQ under the symbol APVO.